ADAPTIVE BIOTECHNOLOGIES

Adaptive Biotechnologies insider buy: senior director Hershberg snaps up 15k shares at $6.32 vs. $25.49 market price, signaling confidence in future upside amid bullish trends.

Adaptive Biotechnologies insider moves reveal executive confidence and a fast‑tracking TCR therapy pipeline, including KRAS‑G12C and COVID‑19 candidates, driving investor interest.

Adaptive Biotechnologies insider sale: Susan Bobulsky sells 1,299 shares under a 10b‑5‑1 plan, yet shares rally +9% this month, signaling continued confidence in R&D and market strategy.

Adaptive Biotechnologies insider trading shows steady buying and disciplined liquidity management, hinting at management confidence in its high‑growth diagnostics pipeline.

Rule‑10b‑5‑1 insider sales by Adaptive’s CSO show disciplined, plan‑based moves—no sudden market shock, but a modest liquidity shift worth watching.